TAMPA and LONDON — November 18, 2025 — Leads & Copy — Akari Therapeutics, Plc (Nasdaq: AKTX) has appointed Kameel D. Farag as its Interim Chief Financial Officer, effective last month. Farag brings over two decades of experience in scaling biotech companies through transformational growth.
Abizer Gaslightwala, President and CEO of Akari Therapeutics, expressed enthusiasm for Farag’s arrival, highlighting his expertise in corporate finance, M&A, and operational build-outs. Gaslightwala believes Farag’s experience will be crucial in accelerating the development of Akari’s novel antibody drug conjugate (ADC) platform and advancing its lead asset toward clinical trials.
Farag shared his excitement about joining Akari, emphasizing the company’s position at the forefront of developing ADCs that disrupt cancer cell survival through RNA splicing modulation. He looks forward to contributing his experience to Akari’s next phase of growth and value creation.
Before joining Akari, Farag was CFO and head of business operations at Aspen Neuroscience, where he oversaw significant growth, secured substantial financing, built manufacturing infrastructure, and prepared the company for potential public offering. He also served as SVP Finance at Ionis Pharmaceuticals, supporting revenue and profitability growth by developing the finance team and systems to manage over $1 billion in revenue and a growing pipeline.
Earlier in his career, Farag spent more than 16 years with Amgen, holding leadership positions focused on driving growth in emerging markets and increasing profitability in established international regions.
Farag holds a bachelor’s degree in Business & Economics from the University of California, Santa Barbara.
Akari Therapeutics is focused on developing next-generation spliceosome payload ADCs. Its ADC discovery platform allows the company to generate and optimize ADC candidates for various targets. Akari’s lead asset, AKTX-101, uses a novel spliceosome modulator payload (PH1) designed to disrupt RNA splicing in cancer cells, inducing cell death and activating immune cells. Preclinical studies have demonstrated significant activity and prolonged survival with AKTX-101, both as a single agent and in combination with checkpoint inhibitors.
The company is generating validating data on its novel payload PH1 to continue advancing its lead asset and other undisclosed targets.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5852f98c-957f-4b32-9046-a609f3d693de
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
Akari Therapeutics, Plc
Kameel D. Farag
Source: Akari Therapeutics, Plc
